297 related articles for article (PubMed ID: 23955995)
1. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
[TBL] [Abstract][Full Text] [Related]
2. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
3. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
[TBL] [Abstract][Full Text] [Related]
5. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
6. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
7. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
9. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
Gastaldelli A; Nauck MA; Balena R
Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
DeFronzo RA; Barzilai N; Simonson DC
J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
[TBL] [Abstract][Full Text] [Related]
11. [The changes of gastrointestinal hormones GLP-1, PYY and ghrelin in patients with newly diagnosed type 2 diabetes mellitus].
Cui T; Ren Y; Ma H; Liu SF; Zhang XX; Yu HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):774-8. PubMed ID: 24325110
[TBL] [Abstract][Full Text] [Related]
12. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
14. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
15. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
16. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
17. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice.
Gao LH; Liu Q; Liu SN; Chen ZY; Li CN; Lei L; Sun SJ; Li LY; Liu JL; Shen ZF
J Ethnopharmacol; 2014; 151(1):675-85. PubMed ID: 24286962
[TBL] [Abstract][Full Text] [Related]
18. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
19. Differences in early-phase insulin secretion and glucose disposition index between aged and middle-aged patients with newly diagnosed type 2 diabetes.
Yu Y; Pan F; Cui W; Tang W; Hu Y
Geriatr Gerontol Int; 2020 Mar; 20(3):206-211. PubMed ID: 31923347
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
